Domača stran038290 • KOSDAQ
add
Macrogen Inc
Prejšnji trg. dan.
16.150,00 ₩
Dnevni razpon
16.210,00 ₩ - 16.650,00 ₩
Letni razpon
14.920,00 ₩ - 26.700,00 ₩
Tržna kapitalizacija
177,01 mrd. KRW
Povprečni obseg
62,86 tis.
Razm. P/E
-
Dividendna donosnost
1,82 %
Primarna borza
KOSDAQ
Borzne novice
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (KRW) | sep. 2024info | Sprememba L/L |
|---|---|---|
Prihodek | 33,00 mrd. | 2,20 % |
Stroški poslovanja | 13,80 mrd. | 4,68 % |
Čisti dohodek | −3,18 mrd. | −60,92 % |
Čista dobičkovnost prihodkov | −9,64 | −57,52 % |
Earnings per share | — | — |
EBITDA | 2,21 mrd. | 47,21 % |
Efektivna davčna stopnja | 1,20 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (KRW) | sep. 2024info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 24,60 mrd. | 8,61 % |
Skupna sredstva | 274,19 mrd. | 3,79 % |
Skupne obveznosti | 124,82 mrd. | 40,99 % |
Celoten lastniški kapital | 149,37 mrd. | — |
Shares outstanding | 9,97 mio. | — |
Razmerje P/B | 1,09 | — |
Donosnost sredstev | −0,54 % | — |
Donosnost kapitala | −0,70 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (KRW) | sep. 2024info | Sprememba L/L |
|---|---|---|
Čisti dohodek | −3,18 mrd. | −60,92 % |
Denar iz dejavnosti | −2,08 mrd. | 50,99 % |
Denar iz naložb | −9,57 mrd. | −22,48 % |
Denar iz financiranja | 6,73 mrd. | 594,06 % |
Neto sprememba denarnih sredstev | −4,51 mrd. | 58,99 % |
Prost denarni tok | −10,07 mrd. | 35,34 % |
Vizitka
Macrogen, Inc. is a South Korean public biotechnology company. The company's headquarters are located in Seoul. The company was founded in 1997 by Jeong-sun Seo, a professor at Seoul National University. It was venture capital-backed until its initial public offering and subsequent listing on the KOSDAQ market in 2000, making it the first Korean biotechnology firm to raise funds through an IPO. The company announced plans in 2010 to map the "Korean genome" based on the notion that United States-backed genome mapping efforts up to that time were representative of the "Caucasian genome" rather than the "Human genome" as claimed. By 2015, the company was described by one news outlet as "a global leader in personalized genomic medicine". Wikipedia
Generalni direktor
Datum ustanovitve
5. jun. 1997
Spletno mesto
Zaposleni
519
